A seven-marker signature and clinical outcome in malignant melanoma: A large-scale tissue-microarray study with two independent patient cohorts

PLoS ONE

Volumn 7, Issue 6, 2012, Pages

  Meyer, Stefanie ^a   Fuchs, Thomas J ^b,e   Bosserhoff, Anja K ^a   Hofstädter, Ferdinand ^a   Pauer, Armin ^c   Roth, Volker ^d   Buhmann, Joachim M ^b,e   Moll, Ingrid ^f   Anagnostou, Nikos ^f   Brandner, Johanna M ^f   Ikenberg, Kristian ^g   Moch, Holger ^g   Landthaler, Michael ^a   Vogt, Thomas ^h   Wild, Peter J ^g  

^a UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^b ETH ZURICH   (Switzerland)

^c Central Tumor Registry Regensburg   (Germany)

^d UNIVERSITY OF BASEL   (Switzerland)

^e Institute of Cell Biology ^*  (Switzerland)

^f UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^g UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^h SAARLAND UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

5' METHYLTHIOADENOSINE PHOSPHORYLASE; BETA CATENIN; CD20 ANTIGEN; CYCLOOXYGENASE 2; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN BAX; PROTEIN BCL X;

ADULT; APOPTOSIS; ARTICLE; B LYMPHOCYTE; CANCER PROGNOSIS; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; CELL ADHESION; CELL CYCLE; CELL DIFFERENTIATION; CELL METABOLISM; CELL PROLIFERATION; CLINICAL ASSESSMENT; COHORT ANALYSIS; CONTROLLED STUDY; CUTANEOUS MELANOMA; DISEASE MARKER; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MISMATCH REPAIR; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIMARY TUMOR; PROTEIN EXPRESSION; RECURRENCE FREE SURVIVAL; RECURRENCE RISK; RETROSPECTIVE STUDY; RISK ASSESSMENT; SIGNAL TRANSDUCTION; TISSUE MICROARRAY;

ADULT; AGED; ANTIGENS, CD20; BCL-2-ASSOCIATED X PROTEIN; BCL-X PROTEIN; BETA CATENIN; CELL LINE, TUMOR; CELLS, CULTURED; COHORT STUDIES; CYCLOOXYGENASE 2; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MALE; MELANOMA; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PTEN PHOSPHOHYDROLASE; PURINE-NUCLEOSIDE PHOSPHORYLASE; SKIN NEOPLASMS; TISSUE ARRAY ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84862001719     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0038222     Document Type: Article

References (40)

1. Jemal A, Siegel R, Xu J, Ward E, (2010) Cancer statistics, 2010. CA Cancer J Clin 60: 277-300.
2. Lens MB, Dawes M, (2004) Global perspectives of contemporary epidemiological trends of cutaneous malignant melanoma. Br J Dermatol 150: 179-185.
3. Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, et al. (2009) Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 27: 6199-6206.
4. Breslow A, (1970) Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg 172: 902-908.
5. Grande Sarpa H, Reinke K, Shaikh L, Shaikh L, Leong SP, Miller JR 3rd, et al. (2006) Prognostic significance of extent of ulceration in primary cutaneous melanoma. Am J Surg Pathol 30: 1396-1400.
6. Morton DL, Thompson JF, Cochran AJ, Mozzillo N, Elashoff R, et al. (2006) Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med 355: 1307-1317.
7. Weinlich G, Eisendle K, Hassler E, Baltaci M, Fritsch PO, et al. (2006) Metallothionein- overexpression as a highly significant prognostic factor in melanoma: a prospective study on 1270 patients. Br J Cancer 94: 835-841.
8. Gould Rothberg BE, Berger AJ, Molinaro AM, Subtil A, Krauthammer MO, et al. (2009) Melanoma prognostic model using tissue microarrays and genetic algorithms. J Clin Oncol 27: 5772-5780.
9. Kashani-Sabet M, Rangel J, Torabian S, Nosrati M, Simko J, et al. (2009) A multi-marker assay to distinguish malignant melanomas from benign nevi. Proc Natl Acad Sci U S A 106: 6268-6272.
10. Gould Rothberg BE, Bracken MB, Rimm DL, (2009) Tissue biomarkers for prognosis in cutaneous melanoma: a systematic review and meta-analysis. J Natl Cancer Inst 101: 452-474.
11. Gould Rothberg BE, Rimm DL, (2010) Biomarkers: the useful and the not so useful-an assessment of molecular prognostic markers for cutaneous melanoma. J Invest Dermatol 130: 1971-1987.
12. Wild PJ, Meyer S, Bataille F, Woenckhaus M, Ameres M, et al. (2006) Tissue microarray analysis of methylthioadenosine phosphorylase protein expression in melanocytic skin tumors. Arch Dermatol 142: 471-476.
13. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, et al. (2005) Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst 97: 1180-1184.
14. Alonso SR, Ortiz P, Pollan M, Perez-Gomez B, Sanchez L, et al. (2004) Progression in cutaneous malignant melanoma is associated with distinct expression profiles: a tissue microarray-based study. Am J Pathol 164: 193-203.
15. Meyer S, Vogt T, Landthaler M, Berand A, Reichle A, et al. (2009) Cyclooxygenase 2 (COX2) and Peroxisome Proliferator-Activated Receptor Gamma (PPARG) Are Stage-Dependent Prognostic Markers of Malignant Melanoma. PPAR Res 2009: 848645.
16. Nocito A, Bubendorf L, Tinner EM, Suess K, Wagner U, et al. (2001) Microarrays of bladder cancer tissue are highly representative of proliferation index and histological grade. J Pathol 194: 349-357.
17. Kaplan EL, Meier P, (1958) Nonparametric Estimation from Incomplete Observations. J Am Stat Assoc 53: 457-481.
18. Mantel N, (1966) Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50: 163-170.
19. Cox DR, (1972) Regression models and life tables. J R Stat Soc Series B 34: 187-220.
20. Benjamini Y, Drai D, Elmer G, Kafkafi N, Golani I, (2001) Controlling the false discovery rate in behavior genetics research. Behav Brain Res 125: 279-284.
21. Bordeaux J, Welsh A, Agarwal S, Killiam E, Baquero M, et al. (2010) Antibody validation. Biotechniques 48: 197-209.
22. Ishwaran H, Kogalur UB, (2010) Consistency of Random Survival Forests. Stat Probab Lett 80: 1056-1064.
23. Hothorn T, Buhlmann P, Dudoit S, Molinaro A, van der Laan MJ, (2006) Survival ensembles. Biostatistics 7: 355-373.
24. Hoek KS, (2007) DNA microarray analyses of melanoma gene expression: a decade in the mines. Pigment Cell Res 20: 466-484.
25. Timar J, Gyorffy B, Raso E, (2010) Gene signature of the metastatic potential of cutaneous melanoma: too much for too little? Clin Exp Metastasis 27: 371-387.
26. Ascierto PA, Kirkwood JM, (2008) Adjuvant therapy of melanoma with interferon: lessons of the past decade. J Transl Med 6: 62.
27. Meyer S, Wild PJ, Vogt T, Bataille F, Ehret C, et al. (2010) Methylthioadenosine phosphorylase represents a predictive marker for response to adjuvant interferon therapy in patients with malignant melanoma. Exp Dermatol 19: e251-257.
28. Denkert C, Kobel M, Pest S, Koch I, Berger S, et al. (2002) Expression of cyclooxygenase 2 is an independent prognostic factor in human ovarian carcinoma. Am J Pathol 160: 893-903.
29. Reichle A, Vogt T, Coras B, Terheyden P, Neuber K, et al. (2007) Targeted combined anti-inflammatory and angiostatic therapy in advanced melanoma: a randomized phase II trial. Melanoma Res 17: 360-364.
30. Azmi AS, Mohammad RM, (2009) Non-peptidic small molecule inhibitors against Bcl-2 for cancer therapy. J Cell Physiol 218: 13-21.
31. Heere-Ress E, Thallinger C, Lucas T, Schlagbauer-Wadl H, Wacheck V, et al. (2002) Bcl-X(L) is a chemoresistance factor in human melanoma cells that can be inhibited by antisense therapy. Int J Cancer 99: 29-34.
32. Avivi I, Robinson S, Goldstone A, (2003) Clinical use of rituximab in haematological malignancies. Br J Cancer 89: 1389-1394.
33. Zabierowski SE, Herlyn M, (2008) Melanoma stem cells: the dark seed of melanoma. J Clin Oncol 26: 2890-2894.
34. Guldberg P, thor Straten P, Birck A, Ahrenkiel V, Kirkin AF, et al. (1997) Disruption of the MMAC1/PTEN gene by deletion or mutation is a frequent event in malignant melanoma. Cancer Res 57: 3660-3663.
35. Stambolic V, Suzuki A, de la Pompa JL, Brothers GM, Mirtsos C, et al. (1998) Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 95: 29-39.
36. Mikhail M, Velazquez E, Shapiro R, Berman R, Pavlick A, et al. (2005) PTEN expression in melanoma: relationship with patient survival, Bcl-2 expression, and proliferation. Clin Cancer Res 11: 5153-5157.
37. Rivera MN, Kim WJ, Wells J, Driscoll DR, Brannigan BW, et al. (2007) An X chromosome gene, WTX, is commonly inactivated in Wilms tumor. Science 315: 642-645.
38. Koesters R, Ridder R, Kopp-Schneider A, Betts D, Adams V, et al. (1999) Mutational activation of the beta-catenin proto-oncogene is a common event in the development of Wilms' tumors. Cancer Res 59: 3880-3882.
39. Fukushima H, Yamamoto H, Itoh F, Horiuchi S, Min Y, et al. (2001) Frequent alterations of the beta-catenin and TCF-4 genes, but not of the APC gene, in colon cancers with high-frequency microsatellite instability. J Exp Clin Cancer Res 20: 553-559.
40. Kuphal S, Bosserhoff AK, (2011) Phosphorylation of beta-catenin results in lack of beta-catenin signaling in melanoma. Int J Oncol 39: 235-243.